SCHEMBL23618155

SCHEMBL23618155

Nc1nc(-c2ccc3c(c2)=CCCC=3)c(Br)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ CD274 Q9NZQ7 1/20 0.37
▸ FBP1 P09467 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ MYC P01106 3/20 0.35
▸ WDR5 P61964 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ MPL P40238 2/20 0.35
▸ KDM4E B2RXH2 3/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ XBP1 P17861 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ CYP3A4 P08684 2/20 0.33
▸ HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23618151 0.82 MPL (0.54) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL23618154 0.82 CD274 (0.56) MAPTMEN1KMT2AHSD17B10CD274
SCHEMBL28651159 0.76 MPL (0.50) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL23610345 0.73 ALDH1A1 (0.50) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL2315152 0.70 MYC (0.54) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL12495409 0.70 HTT (0.55) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL31311302 0.70 MPL (0.47) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL31311233 0.70 MPL (0.50) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL1256622 0.70 MAPT (0.63) MAPTMEN1KMT2AALOX15HSD17B10
SCHEMBL18042050 0.69 ALDH1A1 (0.51) MAPTMEN1KMT2AALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210205275-A1 NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE 2021-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210205275-A1 NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME GAP43, NLN, SMN1; SMN2 MAPT 24/4885MEN1 3116/4885KMT2A 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback